Insiders who reported open-market trades in the last 12 months at the companies Lynn Seely files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Lynn Seely is a corporate insider, tracked as President and CEO, Director of Lyell Immunopharma, Inc. (LYEL). InsiderAlpha holds 11 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Lynn Seely submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Lynn Seely been buying or selling stock?
Recorded transactions: 0 open-market purchases and 9 open-market sales ($438K) across all tracked filings.
Lynn Seely is President and CEO, Director of Lyell Immunopharma, Inc. (LYEL). 11 SEC Form 4 filings on record going back to 2025, most recently on 25 August 2026. Most recent open-market trade: sold $149K of LYEL on 25 August 2026. Lifetime open-market sales: $438K.
Recent transactions
13
The latest 13 SEC Form 4 transactions reported by Lynn Seely.
InsiderAlpha's records for Lynn Seely go back to 2025: 11 primary Form 4 filings, an average of 5.5 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
